Francis Kim
Director, Early Clinical Development, Hematology & Cell Therapy Bristol Myers Squibb
Seminars
Wednesday 25th March 2026
Panel Discussion: Defining Patient Populations for B-Cell Depletion Therapies & Establishing a ‘Window of Opportunity’ for Treatment
3:30 pm
- Determining the optimal time to deploy B-cell depletion, focusing on using ‘immune reset’ therapies early in the course of the disease development
- Comparing the efficacy of standard peripheral B-cell depletion against next-generation therapies designed to achieve a complete, deep-depletion
- Defining new clinical endpoints and securing regulatory approval for a curative-intent treatment that aims to halt disease progression early across a broad, heterogeneous autoimmune patient population
Wednesday 25th March 2026
CD19 NEX-T (BMS-986353) Next-Generation Chimeric Antigen Receptor (CAR) T Cell Therapy in Severe Refractory Autoimmune Diseases
2:00 pm
- Leveraging extensive CAR T cell manufacturing experience to establish the nextgeneration NEX-T manufacturing process
- Assessing the pharmacokinetics and pharmacodynamics of NEX-T CAR T cell therapy in a diverse patient population
- Establishing pooled safety and preliminary efficacy of NEX-T CAR T cell therapy in severe refractory autoimmune diseases
